MDR1/ABCB1 (D3H1Q) Rabbit mAb

• 产品编号：CST-12683S      品牌：CST       原厂货号：12683S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

MDR1/ABCB1 (D3H1Q) Rabbit mAb兔单抗可以识别内源性总MDR1总蛋白水平。单克隆抗体由合成肽段免疫动物产生，该肽段与人MDR1蛋白羧基端附近氨基酸序列一致。MDR1/ABCB1属于ATP结合盒转运蛋白超家族（1）Mdr/Tap亚家族。MDR1作为外源性化合物外排泵具有广泛的底物特异性。它的底物包括治疗剂，如放线菌素D，鬼臼乙叉甙，伊马替尼，阿霉素，以及内源性分子，如β -淀粉样蛋白，类固醇激素，脂质，磷脂，胆固醇和细胞因子（2）。研究表明， MDR1降低了肿瘤细胞中药物的累积，允许药物抗性的发展（3-5）。另一方面，在血-脑，血-脑脊髓液或血液胎盘屏障等器官中，细胞质膜MDR1的表达，限制了药物从顶或浆膜侧到这些器官中的的通透性（6,7）。MDR1基因也在正常组织如小肠，肝脏和肾脏中表达（7）以参与排泄功能。已检测到MDR1在胞内的内质网，囊泡和核膜中有表达，与细胞转运机制相关（8）。 其他已报道的MDR1的功能包括：病毒耐性，细胞因子的转运（9,10），外周和中枢神经系统的脂质平衡（11-13）。

1. Furuya, K.N. et al. (1997) Cancer Res 57, 3708-16.
2. Litman, T. et al. (1997) Biochim Biophys Acta 1361, 169-76.
3. Chen, C.J. et al. (1986) Cell 47, 381-9.
4. Kartner, N. et al. (1983) Cancer Res 43, 4413-9.
5. Chen, G. et al. (1997) J Biol Chem 272, 5974-82.
6. Brinkmann, U. and Eichelbaum, M. (2001) Pharmacogenomics J 1, 59-64.
7. Fromm, M.F. (2004) Trends Pharmacol Sci 25, 423-9.
8. Miller, D.S. et al. (2008) Pharmacol Rev 60, 196-209.
9. Ambudkar, S.V. et al. (1999) Annu Rev Pharmacol Toxicol 39, 361-98.
10. Raviv, Y. et al. (2000) FASEB J 14, 511-5.
11. Meijer, O.C. et al. (2003) J Endocrinol 178, 13-8.
12. Karssen, A.M. et al. (2002) J Endocrinol 175, 251-60.
13. Jeannesson, E. et al. (2009) Clin Chim Acta 403, 198-202.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: Monkey

Specificity / Sensitivity

MDR1/ABCB1 (D3H1Q) Rabbit mAb recognizes endogenous levels of total MDR1 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MDR1 protein.

Background

MDR1/ABCB1 belongs to the Mdr/Tap subfamily of the ATP-binding cassette transporter superfamily (1). Multidrug resistance 1 (MDR1) serves as an efflux pump for xenobiotic compounds with broad substrate specificity. MDR1 substrates include therapeutic agents such as actinomycin D, etoposide, imatinib, and doxorubicin, as well as endogenous molecules including β-amyloids, steroid hormones, lipids, phospholipids, cholesterol, and cytokines (2). Research studies have shown that MDR1 reduces drug accumulation in cancer cells, allowing the development of drug resistance (3-5). On the other hand, MDR1 expressed in the plasma membrane of cells in the blood-brain, blood-cerebral spinal fluid, or blood-placenta barriers restricts the permeability of drugs into these organs from the apical or serosal side (6,7). MDR1 is also expressed in normal tissues with excretory function such as small intestine, liver, and kidney (7). Intracellular MDR1 has been detected in the ER, vesicles, and nuclear envelope, and has been associated with cell trafficking machinery (8). Other reported functions of MDR1 include viral resistance, cytokine trafficking (9,10), and lipid homeostasis in the peripheral and central nervous system (11-13).

1. Furuya, K.N. et al. (1997) Cancer Res 57, 3708-16.
2. Litman, T. et al. (1997) Biochim Biophys Acta 1361, 169-76.
3. Chen, C.J. et al. (1986) Cell 47, 381-9.
4. Kartner, N. et al. (1983) Cancer Res 43, 4413-9.
5. Chen, G. et al. (1997) J Biol Chem 272, 5974-82.
6. Brinkmann, U. and Eichelbaum, M. (2001) Pharmacogenomics J 1, 59-64.
7. Fromm, M.F. (2004) Trends Pharmacol Sci 25, 423-9.
8. Miller, D.S. et al. (2008) Pharmacol Rev 60, 196-209.
9. Ambudkar, S.V. et al. (1999) Annu Rev Pharmacol Toxicol 39, 361-98.
10. Raviv, Y. et al. (2000) FASEB J 14, 511-5.
11. Meijer, O.C. et al. (2003) J Endocrinol 178, 13-8.
12. Karssen, A.M. et al. (2002) J Endocrinol 175, 251-60.
13. Jeannesson, E. et al. (2009) Clin Chim Acta 403, 198-202.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
*Species cross-reactivity is determined by western blot.
** Anti-rabbit secondary antibodies must be used to detect this antibody.